These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16998661)

  • 41. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rising PSA in nonmetastatic prostate cancer.
    Moul JW; Bañez LL; Freedland SJ
    Oncology (Williston Park); 2007 Nov; 21(12):1436-45; discussion 1449, 1452, 1454. PubMed ID: 18077992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rising prostate-specific antigen after primary prostate cancer therapy.
    Ward JF; Moul JW
    Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [PSA recurrence following radical prostatectomy and radiotherapy].
    Fichtner J
    Urologe A; 2006 Oct; 45(10):1255-6, 1258-9. PubMed ID: 17006700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
    Naito S
    Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
    McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
    Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Local recurrence of prostate cancer: hormone therapy].
    Altwein JE; Ebert T
    Urologe A; 2006 Oct; 45(10):1276, 1278-82. PubMed ID: 16998661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation.
    Schmid HP; Keuler FU; Altwein JE
    Urol Int; 2007; 79(2):95-104. PubMed ID: 17851276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
    Mydin AR; Dunne MT; Finn MA; Armstrong JG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
    van den Bergh RC; van Casteren NJ; van den Broeck T; Fordyce ER; Gietzmann WK; Stewart F; MacLennan S; Dabestani S; Bellmunt J; Bolla M; Briers E; Cornford P; Joniau S; Mason MD; Matveev V; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Lam TB; Mottet N
    Eur Urol; 2016 May; 69(5):802-20. PubMed ID: 26691493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.